Clinical trials: NASH
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Iron Depletion Therapy for Type 2 DM and NAFLD
The purpose of this study is to find out whether lowering the amount of iron in the body will result in less resistance to insulin and improved liver function in patients with type 2 diabetes mellitus and non-alcoholic fatty…
- Trial name
- NCT00230087
- Testing
- blood donation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
The primary objective of this study is to evaluate the safety and tolerability of GS-4997 (selonsertib [SEL]) alone or in combination with simtuzumab (SIM) in adults with nonalcoholic steatohepatitis (NASH) and fibrosis stages…
- Trial name
- NCT02466516
- Testing
- SEL, SIM
- Where
- 28 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
Type2 Diabetes
Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics
Metabolic diseases of the liver are silent affections whose morbidity is important. About 70% of patients with type 2 diabetes (T2D) are concerned.
- Trial name
- Quid-Nash (NCT03634098)
- Testing
- new quantitative imaging techniques with contast products, blood sample, second generation tests
- Where
- France
- Volunteers
- 970 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NAFLD, NASH
LITMUS Imaging Study
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD).
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT05479721
- Where
- 18 sites in United States, Finland and 8 more
- Volunteers
- 450 people
- Sponsor
- University of Oxford
NASH - Nonalcoholic Steatohepatitis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
- Trial name
- NCT04897594
- Testing
- TERN-201
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Obesity, Fatty Liver
Impact of Bariatric Surgery on the Evolution of Nonalcoholic Fatty Liver Disease: a Comparative Clinical Trial Between Sleeve Gastrectomy and Gastric Bypass
Aim: To compare prospectively two bariatric surgery techniques: sleeve gastrectomy (SG) vs gastric bypass (GB) in the evolution of nonalcoholic fatty liver disease (NAFLD) measured by the transient elastography in the first year.
- Trial name
- NCT02394353
- Testing
- Transient hepatic elastography
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Brazil
Nonalcoholic Steatohepatitis, NASH
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Parts B and C).
- Trial name
- NCT04565717
- Testing
- ALN-HSD
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Chronic Hepatitis b, Non-Alcoholic Fatty Liver Disease
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled.
- Trial name
- NCT05786963
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Fatty Liver, Diabetes Mellitus, Type 2
Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM
The investigators want to evaluate the effects and safety of ginger in treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- GinLivDM (NCT02289235)
- Testing
- Ginger
- Where
- Iran
- Volunteers
- 76 people
- Sponsor
- Shiraz University of Medical Sciences
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Liver Diseases, Liver Fibrosis
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
- Conditions
- Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis
- Trial name
- NCT03479125
- Testing
- Ultrasound
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Nonalcoholic Fatty Liver Disease
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of the disease which runs a progressive course and may result in liver cirrhosis…
- Trial name
- NCT01210989
- Testing
- Phyllanthus urinaria
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Liver Diseases, Liver Cirrhosis
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
Early screening and monitoring of chronic liver diseases in hepatology practice has become crucial. To achieve this goal, hepatology clinics need simple and available tools at the point-of-care to perform disease severity…
- Conditions
- Liver Diseases, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- DIACEPA (NCT04782050)
- Testing
- Ultrasound liver assessment
- Where
- France
- Volunteers
- 100 people
- Sponsor
- E-Scopics
Non Alcoholic Steatohepatitis
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01766713
- Testing
- Ezetimibe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Obesity, Nonalcoholic Fatty Liver Disease
Fatty Liver Disease in Obese Children
Although weight reduction through physical activity-based interventions is the mainstay therapy for nonalcoholic fatty liver disease (NAFLD), its maintenance is difficult and typically unsuccessful.
- Conditions
- Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
- Trial name
- NCT02117700
- Testing
- N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nemours Children's Clinic
Non-Alcoholic Fatty Liver Disease
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
- Trial name
- NCT04141592
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Queen Mary University of London
NAFLD
Non-alcoholic Fatty Liver Disease and Its Treatment
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT05480007
- Testing
- sitagliptin and metformin, Sitagliptin, Metformin
- Volunteers
- 68 people
- Sponsor
- Shanghai 10th People's Hospital
NAFLD, Insulin Resistance
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian
Getting a rough indicator about the prevalence of different grade of severity of NAFLD (NASH \& liver fibrosis), and Correlate the severity of fatty liver with different serological risk factors of metabolic syndrome and diseases…
- Conditions
- NAFLD, Insulin Resistance, Hepatic Steatosis
- Trial name
- NCT04081571
- Where
- Egypt
- Volunteers
- 1,080 people
- Sponsor
- Cairo University
Fatty Liver, Nonalcoholic, NAFLD
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.
- Conditions
- Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03656744
- Testing
- HTD1801
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.
NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity).
- Trial name
- NCT07900100
- Testing
- Rupatadin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University